749 related articles for article (PubMed ID: 31552017)
1. NK Cell Dysfunction and Checkpoint Immunotherapy.
Bi J; Tian Z
Front Immunol; 2019; 10():1999. PubMed ID: 31552017
[TBL] [Abstract][Full Text] [Related]
2. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
3. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C; Liu Y
Front Immunol; 2020; 11():1295. PubMed ID: 32714324
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
Cao Y; Wang X; Jin T; Tian Y; Dai C; Widarma C; Song R; Xu F
Signal Transduct Target Ther; 2020 Oct; 5(1):250. PubMed ID: 33122640
[TBL] [Abstract][Full Text] [Related]
5. NK Cell-Based Immune Checkpoint Inhibition.
Khan M; Arooj S; Wang H
Front Immunol; 2020; 11():167. PubMed ID: 32117298
[TBL] [Abstract][Full Text] [Related]
6. The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.
Sun H; Sun C
Front Immunol; 2019; 10():2354. PubMed ID: 31681269
[TBL] [Abstract][Full Text] [Related]
7. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.
Blake SJ; Dougall WC; Miles JJ; Teng MW; Smyth MJ
Clin Cancer Res; 2016 Nov; 22(21):5183-5188. PubMed ID: 27620276
[TBL] [Abstract][Full Text] [Related]
8. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer.
Sivori S; Della Chiesa M; Carlomagno S; Quatrini L; Munari E; Vacca P; Tumino N; Mariotti FR; Mingari MC; Pende D; Moretta L
Front Immunol; 2020; 11():2156. PubMed ID: 33013909
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
12. Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors.
Kim N; Lee DH; Choi WS; Yi E; Kim H; Kim JM; Jin HS; Kim HS
BMB Rep; 2021 Jan; 54(1):44-58. PubMed ID: 33298244
[TBL] [Abstract][Full Text] [Related]
13. Harnessing NK Cells for Cancer Treatment.
Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E
Front Immunol; 2019; 10():2836. PubMed ID: 31867006
[TBL] [Abstract][Full Text] [Related]
14. Human NK cells: From surface receptors to clinical applications.
Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
[TBL] [Abstract][Full Text] [Related]
15. PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.
Pesce S; Greppi M; Grossi F; Del Zotto G; Moretta L; Sivori S; Genova C; Marcenaro E
Front Immunol; 2019; 10():1242. PubMed ID: 31214193
[TBL] [Abstract][Full Text] [Related]
16. Exploiting Human NK Cells in Tumor Therapy.
Vacca P; Pietra G; Tumino N; Munari E; Mingari MC; Moretta L
Front Immunol; 2019; 10():3013. PubMed ID: 32010130
[TBL] [Abstract][Full Text] [Related]
17. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
Cifaldi L; Di Santo J; Olive D
Front Immunol; 2020; 11():1132. PubMed ID: 32612604
[No Abstract] [Full Text] [Related]
18. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
19. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
20. The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy.
Souza-Fonseca-Guimaraes F; Cursons J; Huntington ND
Trends Immunol; 2019 Feb; 40(2):142-158. PubMed ID: 30639050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
